CN107596009A - Purposes of the Compound Xueshuantong preparation in kidney damage medicine caused by treatment hypertension is prepared - Google Patents
Purposes of the Compound Xueshuantong preparation in kidney damage medicine caused by treatment hypertension is prepared Download PDFInfo
- Publication number
- CN107596009A CN107596009A CN201710813334.4A CN201710813334A CN107596009A CN 107596009 A CN107596009 A CN 107596009A CN 201710813334 A CN201710813334 A CN 201710813334A CN 107596009 A CN107596009 A CN 107596009A
- Authority
- CN
- China
- Prior art keywords
- kidney
- application
- treatment hypertension
- prepared
- compound xueshuantong
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000009277 Panax notoginseng extract Substances 0.000 title claims abstract description 38
- 210000003734 kidney Anatomy 0.000 title claims abstract description 28
- 150000001875 compounds Chemical class 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 title claims abstract description 19
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 230000006378 damage Effects 0.000 title claims abstract description 13
- 230000036454 renin-angiotensin system Effects 0.000 claims abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
- 206010062237 Renal impairment Diseases 0.000 claims abstract description 5
- 230000005977 kidney dysfunction Effects 0.000 claims abstract description 5
- 230000000740 bleeding effect Effects 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 230000007850 degeneration Effects 0.000 claims description 4
- 230000004064 dysfunction Effects 0.000 claims description 4
- 208000031816 Pathologic Dilatation Diseases 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 230000010248 tubular secretion Effects 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 210000004926 tubular epithelial cell Anatomy 0.000 claims description 2
- 239000003292 glue Substances 0.000 claims 1
- 101001090925 Mus musculus Renin-1 Proteins 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 21
- 210000002966 serum Anatomy 0.000 description 11
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 210000005239 tubule Anatomy 0.000 description 4
- 238000011706 wistar kyoto rat Methods 0.000 description 4
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 3
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 3
- -1 Chloraldurate Substances 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 3
- 229960002478 aldosterone Drugs 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000005084 renal tissue Anatomy 0.000 description 3
- 229940116269 uric acid Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- ATADHKWKHYVBTJ-FVGYRXGTSA-N (R)-adrenaline hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-FVGYRXGTSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 102100028255 Renin Human genes 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N Adrenalin Natural products CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- UCTWMZQNUQWSLP-UHFFFAOYSA-N Adrenaline Natural products CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229940102884 adrenalin Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 229940067131 aspirin 100 mg Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000008383 multiple organ dysfunction Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 210000001957 retinal vein Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses application of the Compound Xueshuantong preparation in kidney damage medicine caused by treatment hypertension is prepared.It is included in and prepares kidney dysfunction medicine caused by treatment hypertension and the application in kidney renin angiotensin aldosterone system disorder medicine.Compared with prior art, the present invention is the multinomial new application for making public for the first time Compound Xueshuantong preparation in kidney damage medicine caused by treatment hypertension is prepared.The medicinal scope of Compound Xueshuantong preparation is expanded.
Description
Technical field
The present invention relates to the multinomial new application of Compound Xueshuantong preparation.Especially treat kidney damage medicine caused by hypertension
Purposes in thing.
Background technology
Hypertension is one of significant risk factor for inducing cardiovascular and cerebrovascular disease, and current domestic hyperpietic reaches 3.3
Hundred million, account for the 30% of global patient.Hypertension includes kidney, the heart, brain etc. with the development of the course of disease, the first target organs of infringement, wherein
Regulation of the kidney for blood volume, electrolyte balance, renin-angiotensin-aldosterone system plays an important roll, and it is damaged
Vicious circle, final multiple organ dysfunction can be formed between hypertension.In addition, in the clinical treatment of cardiovascular and cerebrovascular disease
In, it is medication combined, long-term use of frequently with decompression, lipid-loweringing etc., it is easy to cause overweight kidney to bear.Therefore, kidney is damaged
Harmful protection turns into the key issue for being badly in need of concern in cardiovascular and cerebrovascular clinical treatment, and the recovery to body plays an important roll.
FUFANG XUESHUANTONG JIAONANG is made up of pseudo-ginseng, the red sage root, the Radix Astragali, radix scrophulariae four traditional Chinese medicine material, is the eighties in last century by middle mountain
The Chinese traditional compound medicine that university's Eye Center is developed jointly with Guangdong Zhongsheng Pharmaceutical Co., Ltd, there is promoting blood circulation and removing blood stasis, benefit
The effect of gas yin-nourishing, clinical indication are mainly the retinal vein obstruction and the stability fatigue type heart of blood stasis and syndrome of deficiency of both qi and yin
Angina.Existing patent document CN103655910A, discloses purposes of the FUFANG XUESHUANTONG JIAONANG in terms of liver is protected.However,
The relevant report of purposes of the FUFANG XUESHUANTONG JIAONANG in kidney damage caused by treatment hypertension is there is no at present.
The content of the invention
The present invention feeds original hypertensive rat by high fat and combines cold solidifying stimulation and tested, and finds compound thrombus
Open capsule can significantly inhibit the rise of internal creatinine in serum, uric acid, urea, potassium concentration, be obviously improved Sodium in Serum
Ion concentration, renin-angiotensin-aldosterone system is adjusted, improves the abnormal dilatation of renal tubule and its sky of epithelial cell
Bubble property becomes, and suppresses the microthrombus deposition of kidney.
Thus, the new application the invention discloses Compound Xueshuantong preparation in kidney damage caused by treatment hypertension.
Described kidney damage includes kidney organic disease.Described kidney organic disease is included on tubular ectasia or renal tubule
The solid lesion such as chrotoplast vacuolar degeneration or glomerulus bleeding.
And further disclose, Compound Xueshuantong preparation is in kidney dysfunction medicine caused by treatment hypertension is prepared
Using.Described kidney dysfunction includes detection of glomeruli filtration function obstacle or tubular secretion dysfunction.
Further disclose, Compound Xueshuantong preparation prepare treatment hypertension caused by kidney renin angiotensin-
Application in RAAS disorder medicine.
Compound Xueshuantong preparation of the present invention includes the Chinese medicine composition based on FUFANG XUESHUANTONG JIAONANG prescription
Various be applied to clinical formulations.
The outstanding advantages of the present invention：Compared with prior art, the beneficial effects of the present invention are make public for the first time compound blood
Bolt leads to multinomial new application of the preparation in kidney damage medicine caused by treatment hypertension is prepared.Compound Xueshuantong preparation is expanded
Medicinal scope.
Brief description of the drawings
Fig. 1 embodiment of the present invention each sample observes result figure to experimental rat renal tissues pathology.
Embodiment
With reference to specific embodiment, the present invention will be further described, but the invention is not limited in this.
1. material
(1) animal：SPF levels (specific-pathogen free) male SHR (spontaneously
Hypertensive rats) rat 50, body weight 180-200g；SPF level males WKY (Wistar Kyoto) rat 10, body
Weight 180-220g；There is provided by Beijing Vital River Experimental Animals Technology Co., Ltd..Raise in SPF level Animal Houses, observe room temperature
20 DEG C -23 DEG C, relative humidity 50%-65% of degree, daily illumination in 12 hours.
(2) instrument：The automatic clinical chemistry analyzers of Roche P 800 (Roche, MODULAR P800), ultra low temperature freezer
(Haier, BCD-568W), refrigerated centrifuge (Eppendorf, 5430R), ten a ten thousandth electronic balances (Sartorius,
BP211D), turbula shaker (Scientific Industries Vortex-Genie 2).
(3) reagent：60% fatty heat energy rodent plain particles feed, adrenalin hydrochloride parenteral solution, sodium citrate,
Chloraldurate, physiological saline.Radioimmunoassay (Radio immunity assay, RIA) method detects aldosterone
(green skies biotechnology is limited for (Aldosterone, ALD) and angiotensinⅠ (Angiotensin I, Ang I) kit
Company).
2. method
(1) animal packet and administration：
Normal group：WKY rats 10, give isometric physiological saline.
Model control group：SHR rats randomly select 10, give isometric physiological saline.
Positive control drug (aspirin) group：SHR rats randomly select 10, give aspirin 100mg/kg/d.
FUFANG XUESHUANTONG JIAONANG low dose group：SHR rats randomly select 10, give FUFANG XUESHUANTONG JIAONANG 380mg/
kg/d。
FUFANG XUESHUANTONG JIAONANG middle dose group：SHR rats randomly select 10, give FUFANG XUESHUANTONG JIAONANG 760mg/
kg/d。
FUFANG XUESHUANTONG JIAONANG high dose group：SHR rats randomly select 10, give FUFANG XUESHUANTONG JIAONANG 1520mg/
kg/d。
Animal starts to test after adapting in the environment one week, and wherein FUFANG XUESHUANTONG JIAONANG low dosage is human body clinical equivalent
Dosage.
(2) experimental method：(plain particles feed is given in addition to Normal group WKY rats), and remaining each group SHR rats are given
The rodent of 60% fatty heat energy is given to feed 6 weeks.Each group rat starts to be administered after second week, daily gastric infusion one
It is secondary, administered volume 10ml/kg, successive administration 4 weeks.At the 42nd day, each group SHR rat skin lower injection adrenalin hydrochlorides
(0.8mg/kg), the isometric physiological saline of WKY rat skin lower injections, each group SHR rats immerse ice bath in 0-4 DEG C of frozen water after 2h
Each group SHR rats such as are subcutaneously injected at dosage adrenalin hydrochloride (0.8mg/kg), the WKY rat skin lower injections again after 5min, 2h
Water 12h is can't help in isometric physiological saline, subsequent all equal fasting of rat.Secondary morning, all rats are entered using 10% chloraldurate
Row intraperitoneal injection of anesthesia (0.35mL/100g), 2% iodine carry out abdominal aorta blood sampling, placement with abdominal cavity is opened after sterilization skin
30min, serum (3500r/min, 10min, 4 DEG C) is centrifuged to obtain, take 600 μ L serum samples automatically to be given birth to using Roche P800
Change instrument detection carbon dioxide combining power (Carbon Dioxide Combining Power, CDCP), creatinine (Creatinine,
Cr), urea (Urea, Ur), uric acid (Uric acid, UA), serum potassium (Serum kalium, SK), serum sodium (Serum
Natrium, SNa)；300 μ L serum samples are taken using radio-immune method kit detection renin activity (Plasma renin
Activity, PRA), aldosterone Aaldosterone, ALD).After taking blood, rat kidney tissue is taken out immediately with 10% buffering good fortune
Your Malin fixes 24h, makes paraffin section, carries out hematoxylin eosin staining (Hematoxylin-eosin, HE), shows in optics
Observed under micro mirror, the main substantial damage situation for investigating kidney, whether there is inflammatory reaction, whether there is excess adipose and microthrombus heap
Product phenomenon etc..
(3) data processing：Data are presented using means standard deviation, group difference statistics one-way analysis of variance side
Method, the softwares of SPSS 19.0 realize that P values are thought with significant difference less than 0.05 or 0.01.
3. experimental result
(1) protection of the FUFANG XUESHUANTONG JIAONANG to renal function：
As shown in Table 1, compared with Normal group, CDCP, Cr, Ur, UA, SK, SNa of model control group rat occur to show
Write and change.Serum K+(SK) rise is common in kidney failure, and serum N a+(SNa) reduction not only occurs in kidney failure, goes back normal
See in the cases such as encephaledema, intracranial pressure rise.Detection of glomeruli filtration function obstacle and kidney are then prompted in Cr, Ur, UA notable rise
Tubular secretion dysfunction.These parameters indicate renal function and obstacle occur.The basic, normal, high dosage group of FUFANG XUESHUANTONG JIAONANG
The change of kidney biochemical indicator can be significantly improved, and a certain amount effect relation is presented, that is, has played the effect of protection kidney.
There was no significant difference compared with model control group for aspirin group.
(2) regulation of the FUFANG XUESHUANTONG JIAONANG to renin-angiotensin-aldosterone system (RAAS)：
As shown in Table 2, compared with Normal group, the PRA of model control group rat is remarkably decreased, and ALD is significantly raised,
RAAS systems get muddled.Excessive ALD can produce many influences to body, and it can promote water and Na+ reabsorption, from
And cause the further rise of blood pressure；Suppress NO release, cause function of vascular endothelium to be damaged；The remodeling of cardiac muscle cell is influenceed,
Cause vascular smooth muscle cells to ossify, cardiac dysfunction is further aggravated.The basic, normal, high dosage group of FUFANG XUESHUANTONG JIAONANG is equal
PRA decline and ALD rise can be significantly inhibited, and a certain amount effect relation is presented, indicates its regulation to RAAS systems
Effect.There was no significant difference compared with model control group for aspirin group.
Protection of the FUFANG XUESHUANTONG JIAONANG of table 1 to renal function
Note：Compared with model group：* P ＜ 0.05, * * P ＜ 0.01；Compared with normal group：#P ＜ 0.05,##P ＜ 0.01.
Regulation of the FUFANG XUESHUANTONG JIAONANG of table 2 to renin-angiotensin-aldosterone system (RAAS)
Note：Compared with model group：* P ＜ 0.05, * * P ＜ 0.01；Compared with normal group：#P ＜ 0.05,##P ＜ 0.01.
(3) influence of the FUFANG XUESHUANTONG JIAONANG to renal tissues pathology：
As shown in Figure 1, the glomerulus of rats in normal control group is clear in structure, renal tubule marshalling, has no expansion and withers
Contracting, has no obvious thrombus and bleeding.The part tubular ectasia (20%-30%) of model control group rat, part kidney
Tubular epithelial cell vacuolar degeneration (20%-30%), and glomerulus has obvious bleeding, it is seen that thrombosis.Compound
The basic, normal, high dosage of XUESHUANTONG JIAONANG can effectively reduce the expansion of renal tubule, improve the vacuolar degeneration of renal cells,
Low, middle dosage still has a small amount of bleeding, and high dose then has no obvious thrombus and bleeding.Aspirin group and model pair
According between group without significant difference.Above-mentioned pathological section result shows that there is protection to make for damage of the FUFANG XUESHUANTONG JIAONANG to kidney
With.
It is theoretical by traditional Chinese medical science prescription, based on all prescriptions by FUFANG XUESHUANTONG JIAONANG, add and subtract or other change gained have
The Chinese medicine composition of same or similar effect is equal to Compound Xueshuantong preparation, within the scope of the present invention.
Claims (7)
1. application of the Compound Xueshuantong preparation in kidney damage medicine caused by treatment hypertension is prepared.
2. application as claimed in claim 1, it is characterised in that described kidney damage includes kidney organic disease.
3. application as claimed in claim 2, it is characterised in that described kidney organic disease includes tubular ectasia or kidney
Tubular epithelial cell vacuolar degeneration or glomerulus bleeding.
4. application of the Compound Xueshuantong preparation in kidney dysfunction medicine caused by treatment hypertension is prepared.
5. application as claimed in claim 4, it is characterised in that described kidney dysfunction hinders including detection of glomeruli filtration function
Hinder or tubular secretion dysfunction.
6. Compound Xueshuantong preparation is preparing kidney renin-angiotensin-aldosterone system disorder caused by treatment hypertension
Application in medicine.
7. the application as described in claim 1 to 6, it is characterised in that described Compound Xueshuantong preparation is Compound Xueshuantong glue
Capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710813334.4A CN107596009B (en) | 2017-09-11 | 2017-09-11 | Application of compound thrombus clearing preparation in preparing medicine for treating renal damage caused by hypertension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710813334.4A CN107596009B (en) | 2017-09-11 | 2017-09-11 | Application of compound thrombus clearing preparation in preparing medicine for treating renal damage caused by hypertension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107596009A true CN107596009A (en) | 2018-01-19 |
| CN107596009B CN107596009B (en) | 2021-02-23 |
Family
ID=61063422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710813334.4A Active CN107596009B (en) | 2017-09-11 | 2017-09-11 | Application of compound thrombus clearing preparation in preparing medicine for treating renal damage caused by hypertension |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107596009B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103655909A (en) * | 2013-12-23 | 2014-03-26 | 广东众生药业股份有限公司 | Application of compound thrombosis capsule in aspect of kidney protection |
| CN104147032A (en) * | 2014-07-29 | 2014-11-19 | 广东众生药业股份有限公司 | Drug composition for preventing and treating related diseases of ischemic stroke as well as preparation method and applications thereof |
-
2017
- 2017-09-11 CN CN201710813334.4A patent/CN107596009B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103655909A (en) * | 2013-12-23 | 2014-03-26 | 广东众生药业股份有限公司 | Application of compound thrombosis capsule in aspect of kidney protection |
| CN104147032A (en) * | 2014-07-29 | 2014-11-19 | 广东众生药业股份有限公司 | Drug composition for preventing and treating related diseases of ischemic stroke as well as preparation method and applications thereof |
Non-Patent Citations (2)
| Title |
|---|
| 张晓慧: "复方血栓通治疗原发性高血压的疗效观察及对血清尿酸、超敏C反应蛋白和同型半胱氨酸水平的影响", 《医学信息》 * |
| 许利平: "《实用中成药手册》", 31 October 2010, 中国中医药出版社 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107596009B (en) | 2021-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wöhrl et al. | Histamine intolerance-like symptoms in healthy volunteers after oral provocation with liquid histamine. | |
| Russcher et al. | The role of melatonin treatment in chronic kidney disease | |
| US20210322407A1 (en) | Use of Trimetazidine in Preparation of Drugs for Preventing and Treating Liver Diseases | |
| Alameddine et al. | The cardiovascular effects of salidroside in the Goto-Kakizaki diabetic rat model | |
| CN107427502A (en) | Use the smooth treatment method of valley | |
| Dai et al. | Central infusion of angiotensin ii type 2 receptor agonist compound 21 attenuates DOCA/Nacl‐induced hypertension in female rats | |
| Liu et al. | Discovery of a novel rice-derived peptide with significant anti-gout potency | |
| Kettritz et al. | Potassium homeostasis–Physiology and pharmacology in a clinical context | |
| CN102283836B (en) | Application of sorafenib in treatment of early brain injury (EBI) after subarachnoid hemorrhage (SAH) | |
| TWI472519B (en) | N-butylidenephthalide-containing pharmaceutical composition for treating liver injury and improving liver function | |
| CN107596009A (en) | Purposes of the Compound Xueshuantong preparation in kidney damage medicine caused by treatment hypertension is prepared | |
| CN102068513B (en) | Application of coptis astragalus scutellaria composition in preparation of drug for preventing and treating diabetic complication | |
| CN104814954B (en) | A kind of pharmaceutical preparation and the application in treatment myocardial ischemia and gastritis medicine is prepared | |
| Wojtaszek et al. | Peritoneal ultrafiltration in end-stage congestive heart failure | |
| CN103417565B (en) | The application of depolymerization glycosaminoglycan extracted from sea cucumber in preparation control thrombotic diseases medicine | |
| CN112972470A (en) | Pharmaceutical composition for preventing and treating cardiorenal syndrome and application thereof | |
| CN110448562A (en) | Application of the lupenone in preparation treatment renal damage drug | |
| CN104547388A (en) | Traditional Chinese medicine composition for treating alzheimer disease, as well as preparation method and application thereof | |
| CN103948780B (en) | A kind of medicine and capsule for constipation | |
| CN109820903A (en) | A kind of Chinese medicine composition and the preparation method and application thereof for treating diabetic nephropathy | |
| Liu et al. | Mechanistic study of lipid metabolism disorders in diabetic kidney disease treated with GLQMP based on network pharmacology, molecular docking and vitro experiments | |
| CN103656485B (en) | It is a kind of to treat dull-witted Chinese medicine composition and preparation method thereof | |
| CN102755637B (en) | Composition for preventing and treating ischemia reperfusion injury | |
| CN107349318B (en) | Blood fat reducing pericarpium trichosanthis compound and preparation method thereof | |
| Rudhani et al. | Pentoxyfilline Effect on Reduction of Proteinuria to PATIENTS With Diabet Type-2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |